Haruko Daga

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita et al. · Journal of Clinical Oncology · 2016 · 160 citations

Medicine, Oncology, Pharmacology +17

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu et al. · International Journal of Clinical Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Metastasis +12

Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard et al. · Clinical Cancer Research · 2021 · 140 citations · Full text

Medicine, Oncology, Molecular Oncology +15